Address
60 Gracechurch Street
London, EC3V 0HR
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1223 627222
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
December 17, 2015
| Name | Title | Pay | Year Born |
| Daniel John Gooding | Executive Director | 30,000 | 1973 |
| Joanne Holland | Consultant | 0 | 1975 |
| Shaun Zulafqar | Company Secretary | 0 | N/A |
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.